Decoding Dementia: Dr. Emma Mead on the Future of Alzheimer’s Therapies

Dr. Emma Mead is the Chief Scientific Officer at the Oxford Drug Discovery Institute. In this episode, we explore with her the cutting-edge science behind Alzheimer’s and other neurodegenerative diseases.

Dr. Mead takes us through the journey from groundbreaking genetic discoveries to the development of potential therapies, explaining how tiny brain cells called microglia could hold the key to preventing and slowing dementia.

We dive into the complexities of Alzheimer’s beyond amyloid plaques, the promise of targeting genes like PLCG2, and the innovative approaches to drug discovery—from identifying molecular “hits” in the lab to partnering with pharmaceutical companies for clinical trials. Emma also shares her vision for a future where patients benefit from a toolbox of personalised treatments, early diagnosis, and improved quality of life.

This episode offers hope, insight, and a human perspective on a disease that affects one in two of us, directly or indirectly. Whether you’re a researcher, carer, or someone interested in the future of neuroscience, this conversation highlights why the next decade could transform dementia care.

If you have any questions for Justine and Prof Julie. Email us [e-mail].

For further help and advice please visit
https://www.alzheimers.org.uk.